In vitro evaluation of a large chemical library of pharmacologically acceptable prototpe compounds in a
). An HIV-1 strain containing the Tyrl1 -) Cys mutation in the reverse transcriptase region displayed reduced sensitivity. a-APA derivative R 89439 inhibited virion and recombiant reverse transciptase of HIV-1 but did not inhibit that of HIV-2. Reverse transcriptase inhibition depended upon the template/primer used. The relatively uncomplicated synthesis of R 89439, its potent anti-HIV-1 activity, and its favorable pharmacokinetic profie make R 89439 a good candidate for clinical studies.
As of 1992, the World Health Organisation (WHO) estimates that worldwide -10 million people are infected with the human immunodeficiency virus (HIV). In particular, Africa; Southeast Asia, and South America are now faced with a rapidly growing number of HIV infections. In addition to preventive campaigns and treatment of opportunistic diseases, managing and counteracting the HIV/AIDS pandemic also requires effective antiviral therapy. Ideally, anti-HIV drugs should be highly selective, have good oral availability and favorable pharmacokinetics, and allow large-scale production at reasonable costs to bring them within reach of more of the world population.
We described previously a family of highly potent and selective reverse transcriptase (RT) inhibitors, the tetrahydroimidazo [4,5,1-jkl [1, 4] benzodiazepin-2(1H)-one and -thione (TIBO) derivatives that exhibit distinctive specificity for HIV-1 (1, 2) (4) , the dipyridodiazepinones (5), the pyridinones (6) , and the bis(heteroaryl)piperazines (7) . All of these compounds interact allosterically with the RT-template/primer complex (1, 2, 5-9).
Here we describe another chemical family of HIV-1-specific RT inhibitors, the a-anilinophenylacetamide (a-APA) derivatives, which inhibit HIV-1 replication in vitro at nanomolar concentrations 10,000-to 100,000-fold lower than their cytotoxic concentrations. One of them, R 89439, has good oral availability and favorable pharmacokinetics and can be easily synthesized on a large scale.
MATERIALS AND METHODS
Compounds. The a-APA derivatives were prepared from 2,6-dichlorobenzaldehyde, a substituted aniline, and sodium cyanide in acetic acid (10), followed by hydrolysis of the intermediate aminonitrile in sulfuric acid (11) . The radiolabeled a-APA derivative R 18893 and its two enantiomers R 87231 and R 87232 were synthesized by tritiation of 3-bromo-2,6-dichlorobenzylalcohol to 2,6-dichloro-3-tritiobenzylalcohol. Oxidation to the benzaldehyde, aminonitrile synthesis with 2-nitroaniline, and hydrolysis gave the 3H-labeled R 18893 in a 40% radiochemical yield. Resolution by means of HPLC over a chiral column (ChiralCel O.J.) afforded both enantiomers with enantiomeric excess >99%o (261 GBq/ nmol, radiochemical purity >99.0%6). (14) ; SIV., (15) ; SIV,mndGBl (16) . The HIV-1 mutant strains 13MB1 (Leu00 -) Ile) and 13CN1 (Tyrl81 -* Cys) were isolated in our laboratory after serial passage ofthe IIIB/LAI strain (MT-4 cells) and the NDK strain (CEM) cells, respectively, in the presence of TIBO R 82913 at 0.5 ,tg/ml (unpublished data).
Antiviral Assays. These assays have been described in more detail elsewhere (1, 17 MgCl2, 100 mM KCI, 4 mM dithiothreitol, 30 mg of bovine serum albumin per ml, 0.5 mM EGTA, and 0.01% (wt/vol) Triton X-100. Of the four deoxynucleotides (dNTPs), three were used at a saturating concentration of 100 AM, whereas the tritium-labeled dGTP (Amersham) was used at a concentration of 2.5 ,uM. (Fig. 1) . Cytotoxicity was seen at a 25-fold higher concentration. Through evaluation of structurally related compounds we identified R 18893 as a more potent inhibitor of HIV-1 replication with an IC50 of 88 nM (Fig. 1 ). This increased potency was not paralleled by higher cytotoxicity, as the selectivity index [ratio of the 50% cytotoxic concentration (CCso) to IC50] was 909. A program of synthesis was subsequently initiated, aimed at enhancing the anti-HIV potency. The HIV-1 iihibition of R 18893 appeared to be stereospecific because the newly synthesized (-)-isomer R 87232 was 50-fold more potent (IC50, 33 nM) as compared with the (+)-isomer R 87231 (IC50, 1700 nM) (Fig. 1) . When the nitro-substituent in the aniline moiety of the a-APA structure was replaced by an acetyl group (R 88703), the anti-HIV-1 activity increased (IC50, 26 nM). The potency was further optimized by introducing an additional methyl group in the 5-position of the aniline moiety. This a-APA derivative, R 89439, had an IC5o of 13 nM and a selectivity index of 54,614. The stereospecificity seen for the enantiomers of R 18893 extended to these derivatives. The (-)-isomer of R 89439, R 90385, was the most potent of the series; it had an IC50 of S nM and a selectivity index of 84,000. Under similar assay conditions, dideoxyinosine (ddI) and 3'-azido-3'-deoxythymidine (AZT) had an IC50 of 4800 nM and 0.5 nM, respectively (Fig. 1) .
RESULTS
Antiretroviral Activity Profile of a-APA Derivative R 89439.
Next we examined the possible role of different host cell systems and the susceptibility of different retroviruses to R 89439, ddI, and AZT (Table 1) . In phytohemagglutininstimulated peripheral blood lymphocyte cultures, HIV-1 infection was monitored by measuring the viral p24 core production in the cell supernatant at 8 days p.i. Under these conditions R 89439 achieved a median 50%1o inhibition at 14 nM (Table 1) . R 89439 and R 18893 proved >90%o protective at "'100 and 600 nM, respectively. In the non-human T-lymphotropic virus type I-transformed CD4+ T-cell line CEM, R 89439 inhibited HIV-1 antigen expression, as measured by FACS analysis at an IC50 of 4 nM ( Table 1) .
We subsequently investigated the sensitivity of a number of HIV-1 strains to R 89439 inhibition in MT-4 cells ( Table 1 The combined anti-HIV-1 activity of a-APA derivative R 89439 with either AZT, ddI, and the protease inhibitor Ro 318959 proved to be synergistic (data not shown).
Mechanism of Action Studies. The drug-sensitive phase in the HIV-1 replicative cycle was determined by a time of addition experiment in which equipotent drug concentrations (i.e., 100-fold IC50 concentrations) were added at different times p.i. to MT4 cells (Fig. 2) . Analysis ofp24 antigen levels shortly after the end of the first replicative cycle indicated RT Inhibition by a-APA Derivatives. R 89439 inhibited a poly(A)-(dT)12_18-and a poly(C) (dG)12.18-driven RT reaction by 50% at 3.1 and 0.1 AM, respectively (Table 2) . A poly(dC) (dG)12_18-directed polymerase reaction was inhibited by 50% at 1.3 ,uM. The RT inhibition by a-APA derivatives was stereospecific because the (+)-isomer of R 18893 (R 87231) was >150-fold less active (IC50, 67 ,AM) than the (-)-isomer R 87232 (IC50, 0.4 ,uM) (Fig. 1) . When a tritium label was introduced in the latter three a-APA derivatives and their RT-binding properties were investigated in equilibrium dialysis experiments, the same stereospecificity as well as the template-dependent pattern became apparent (data not shown). Also within a series of a-APA derivatives, a correlation was found when the IC50 values for inhibition of HIV-1 replication were compared with the IC50 values for RT inhibition (Fig. 1) . Enzyme kinetic analysis of RT inhibition by R 89439 indicated that the effects were noncompetitive with respect to the substrate dGTP (Ki, 0.34 uM) and the template/primer poly(C) (dG)i2_j8 (data not shown). HIV-1 RT mutants obtained by site-directed mutagenesis in which Tyr'81 was replaced by either cysteine or isoleucine, displayed reduced sensitivity by, at least, a factor of 250 and 1250, respectively. Similarly, the Tyr88 Leu mutation also led to >1250-fold reduction in sensitivity (Table 2) .
Pharmacokinetic Profile of a-APA Derivatives. To select a suitable candidate for clinical evaluation, four a-APA derivatives were tested in healthy male volunteers. The plasma levels of the active (-) enantiomers were determined by enantioselective HPLC. 
